Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Nicolas Penel et al.|Journal of Thoracic Oncology|2019Cited by 437
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al.|Journal of Clinical Oncology|2018Cited by 208
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A. Konstantinopoulos, Ronnie Shapira‐Frommer, Jungmin Lee et al.|Gynecologic Oncology|2022Cited by 66
Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in AustraliaEmma L. Boys, Jia Liu, Bo Gao et al.|Cancer Medicine|2024Cited by 8
153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)JC Goh, Michael Millward, Jermaine Coward et al.|Annals of Oncology|2021Cited by 3